epiafzelechin and Alzheimer-Disease

epiafzelechin has been researched along with Alzheimer-Disease* in 1 studies

Other Studies

1 other study(ies) available for epiafzelechin and Alzheimer-Disease

ArticleYear
Carboxymethylated-kappa-casein: a convenient tool for the identification of polyphenolic inhibitors of amyloid fibril formation.
    Bioorganic & medicinal chemistry, 2010, Jan-01, Volume: 18, Issue:1

    Reduced and carboxymethylated-kappa-casein (RCM-kappa-CN) is a milk-derived amyloidogenic protein that readily undergoes nucleation-dependent aggregation and amyloid fibril formation via a similar pathway to disease-specific amyloidogenic peptides like amyloid beta (Abeta), which is associated with Alzheimer's disease. In this study, a series of flavonoids, many known to be inhibitors of Abeta fibril formation, were screened for their ability to inhibit RCM-kappa-CN fibrilisation, and the results were compared with literature data on Abeta inhibition. Flavonoids that had a high degree of hydroxylation and molecular planarity gave good inhibition of RCM-kappa-CN fibril formation. IC(50) values were between 10- and 200-fold higher with RCM-kappa-CN than literature results for Abeta fibril inhibition, however, with few exceptions, they showed a similar trend in potency. The convenience and reproducibility of the RCM-kappa-CN assay make it an economic alternative first screen for Abeta inhibitory activity, especially for use with large compound libraries.

    Topics: Alzheimer Disease; Amyloid; Amyloid beta-Peptides; Animals; Caseins; Flavonoids; Humans; Methylation; Milk; Structure-Activity Relationship

2010